Increasing the participation of African American men in prostate cancer clinical trials through education, awareness, support and collaborations. This portal provides clinical trials background information, details for specific trials, personal stories and other resources to support the Rally.
This information is not intended as medical advice for patients. Patients should consult their medical doctor for advice and recommendations about specific clinical trials.
"We must not be left behind with new prostate cancer treatments."
PHEN president and founder Thomas A. Farrington talks about his prostate cancer journey and the importance of African American men participating in clinical trials.
Information
|
Understanding the possible benefits for patients when participating in a clinical trial.
Clinical trials offer important and unique benefits to patients.
Information
|
Dr. J. Carter Presents Clinical Trials 101
Dr. Carter's brief video presentations provide basic information for patients to better understand clinical trials.
Information
|
What Are Clinical Trials?
Information that all patients need to know when considering enrolling into a clinical trial.
Information
|
A Clinical Trials Guide for Patients
Patient information on why clinical trials matter, how clinical trials work, what to expect, myths and facts. Information provided by Sanofi.
Information
|
AMG 160
This study is investigating the safety and effects (good or bad) of using AMG 160 alone or with pembrolizumab (Keytruda) to treat metastatic castration resistant prostate cancer (mCRPC), which has spread to other parts of the body and is resistant to standard hormonal therapies.
Information
|
AMG 509
This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.
Information
|
Checkmate 650
This clinical trial is for patients who have metastatic castration resistant Prostate Cancer (mCPRC) that has progressed while on Docetaxel. This trial is investigating the safety and effects (good or bad) of specific doses of Ipilimumab along with Nivolumab in patients with prostate cancer. Nivolumab and ipilimumab are investigational immunotherapies, which means that they are not currently approved to treat metastatic prostate cancer.
Information
|
CheckMate 7DX
The purpose of this study is to test the safety and efficacy of nivolumab with docetaxel in men with advanced castration resistant prostate cancer (mCRPC), who have progressed after second-generation hormonal manipulation. Patients eligible to participate in this study will receive Nivolumab, docetaxel, and prednisone or docetaxel, prednisone, and placebo.
Information
|
Triton 3 Clinical Trial
For patients where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of BRCA1, BRCA2, or ATM genetic mutations or alterations
Information
|
Amplitude
The AMPLITUDE study is looking for men with newly diagnosed metastatic prostate cancer.
Information
|
APA RP
The APA RP study is looking for men with prostate cancer at high risk of metastasis and who have recently undergone or are planning to undergo radical prostatectomy (RP) surgery.
Information
|
MAGNITUDE
The MAGNITUDE Study is a Phase 3 randomized, placebo-controlled, double-blind study comparing a combination of an investigational medicine and standard treatment , to a combination of a placebo and standard treatment for men with metastatic prostate cancer.
Information
|
PROTEUS
The PROTEUS study is a randomized, double-blind, placebo-controlled, phase 3 study of an investigational drug in subjects with high-risk, localized or locally advanced prostate cancer who are candidates for radical prostatectomy.
Information
|
KEYLYNK 010
This clinical trial is for men who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond abiraterone acetate or enzalutamide (but not both) and to chemotherapy.
Information
|
KEYNOTE 641
This clinical trial is for men with metastatic castration-resistant prostate cancer (mCRPC) and is trying to find out if combining pembrolizumab and enzalutamide can slow down prostate cancer.
Information
|
KEYNOTE 921
This clinical trial is for men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy, and failed prior treatment with enzalutamide, abiraterone, and apalutamide.
Information
|
KEYNOTE 991
This clinical trial is for men with Metastatic Hormone- Sensitive prostate cancer (mHSPC) whose prostate cancer has responded to Androgen Deprivation Therapy (ADT).
Information
|
TALAPRO-2
This trial is for patients with metastatic Castration-Resistant Prostate Cancer who have not received prior treatment for Castrate-Resistant disease.
Information
|
Low and Intermediate Risk Prostate Cancer
Clinical trials for patients who are diagnosed with low and intermediate risk prostate cancer (Gleason 6 or 7). Patients may be interested in active surveillance or making a decision to begin active treatment.
Information
|
High Risk Prostate Cancer
Clinical trials for patients diagnosed with high risk prostate cancer (Gleason 8 - 10). Patients may be deciding on an active treatment protocol.
Information
|
Prostate Cancer Treated with Prostatectomy or Radiation
Clinical trials for patients who have been treated with surgery or radiation. Patients may be seeking to reduce the risk of recurrence following primary treatment or interested in quality of life studies.
Information
|
Recurrent Prostate Cancer
Clinical trials for patients who have a recurrence of prostate cancer following primary treatment with surgery or radiation.These patients have not yet begun treatment with androgen deprivation therapy.
Information
|
Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)
Clinical trials for patients whose PSA rises while they are on androgen deprivation therapy but prostate cancer has not metastasized.
Information
|
Metastatic Castration Resistant Prostate Cancer (MCRPC) Patients
Clinical trials for patients diagnosed with metastatic prostate cancer that no longer responds to androgen deprivation treatment. Patients who are seeking treatment options following a diagnosis of MCRPC.
Information
|
